Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund S G, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E
Department of Internal Medicine at Karolinska Hospital, Stockholm, Sweden.
N Engl J Med. 1997 Feb 6;336(6):393-8. doi: 10.1056/NEJM199702063360601.
A consensus has not been reached about the optimal duration of oral anticoagulant therapy after a second episode of venous thromboembolism.
In a multicenter trial, we compared six months of oral anticoagulant therapy with anticoagulant therapy continued indefinitely in patients who had had a second episode of venous thromboembolism. Of 227 patients enrolled, 111 were randomly assigned to six months of anticoagulation and 116 were assigned to receive anticoagulant therapy indefinitely; for both groups, the target international normalized ratio was 2.0 to 2.85. The initial episodes of deep-vein thrombosis (n = 193) and pulmonary embolism (n = 34), as well as recurrent episodes, were all objectively confirmed.
After four years of follow-up, there were 26 recurrences of venous thromboembolism that fulfilled the diagnostic criteria, 23 in the group assigned to six months of therapy (20.7 percent) and 3 in the group assigned to continuing therapy (2.6 percent). The relative risk of recurrence in the group assigned to six months of therapy, as compared with the group assigned to therapy of indefinite duration, was 8.0 (95 percent confidence interval, 2.5 to 25.9). There were 13 major hemorrhages, 3 in the six-month group, (2.7 percent) and 10 in the infinite-treatment group (8.6 percent). The relative risk of major hemorrhage in the six-month group, as compared with the infinite-treatment group was 0.3 (95 percent confidence interval, 0.1 to 1.1). There was no difference in mortality between the two groups.
Prophylactic oral anticoagulation that was continued for an indefinite period after a second episode of venous thromboembolism was associated with a much lower rate of recurrence during four years of follow-up than treatment for six months. However, there was a trend toward a higher risk of major hemorrhage when anticoagulation was continued indefinitely.
对于第二次静脉血栓栓塞发作后口服抗凝治疗的最佳持续时间尚未达成共识。
在一项多中心试验中,我们比较了第二次静脉血栓栓塞发作患者接受6个月口服抗凝治疗与无限期持续抗凝治疗的效果。在227名入组患者中,111名被随机分配接受6个月抗凝治疗,116名被分配接受无限期抗凝治疗;两组的目标国际标准化比值均为2.0至2.85。深静脉血栓形成(n = 193)和肺栓塞(n = 34)的初始发作以及复发发作均经客观证实。
经过4年随访,有26例静脉血栓栓塞复发符合诊断标准,6个月治疗组有(20.7%)23例,持续治疗组有3例(2.6%)。与无限期治疗组相比,6个月治疗组复发的相对风险为8.0(95%置信区间,2.5至25.9)。有13例严重出血事件,6个月组有3例(2.7%),无限期治疗组有10例(8.6%)。与无限期治疗组相比,6个月组严重出血的相对风险为0.3(95%置信区间,0.1至1.1)。两组死亡率无差异。
第二次静脉血栓栓塞发作后无限期持续预防性口服抗凝治疗在4年随访期间的复发率远低于6个月治疗。然而,无限期持续抗凝治疗时严重出血风险有升高趋势。